Bearish
Johnson & Johnson (JNJ) stock drops 1.21% amid $4 billion patent expiry concerns
Johnson & Johnson's (JNJ) stock declined by 1.21% to $252.93 on October 5, 2026, amid concerns over upcoming patent expirations in 2027, potentially impacting $4 billion in revenue. Despite this, the company reported positive Phase 3 ICOTYDE study results, showing 70% of patients achieved clear or almost clear skin at Week 112. Additionally, institutional investors have been adjusting their positions, with Park National Corp OH reducing its stake by 4.8% in the third quarter.
Key points
- Patent expirations in 2027 could lead to a $4 billion revenue impact.
- ICOTYDE Phase 3 study shows 70% of patients with clear or almost clear skin at Week 112.
- Park National Corp OH reduced its JNJ stake by 4.8% in Q3.
Sources
AI-generated from public news sources. Not financial advice.
